Schumann et al. demonstrated that plasma concentration of matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-4 and tenascin C, a matricellular protein, was elevated in the patients with PAH [16]. This evidence concerns the gene MMP2 and pulmonary arterial hypertension.